trastuzumab emtansine

Trastuzumab emtansine (also known as T-DM1) is a targeted cancer therapy used mainly for HER2-positive breast cancer. It combines the antibody trastuzumab, which specifically binds to cancer cells with high levels of the HER2 protein, with a chemotherapy drug called DM1 that kills the cancer cells. When administered, T-DM1 attaches to HER2-positive cancer cells and delivers the chemotherapy directly to them, minimizing damage to healthy cells. This targeted approach aims to improve treatment effectiveness while reducing side effects associated with traditional chemotherapy.